Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3,373 Comments
1,330 Likes
1
Pebbles
Consistent User
2 hours ago
How do you even come up with this stuff? ๐คฏ
๐ 127
Reply
2
Piers
Daily Reader
5 hours ago
That was ridiculously good. ๐
๐ 169
Reply
3
Brigida
Community Member
1 day ago
Pure talent, no cap. ๐งข
๐ 79
Reply
4
Margy
Trusted Reader
1 day ago
Thatโs smoother than silk. ๐งต
๐ 124
Reply
5
Angelisse
Experienced Member
2 days ago
Someone call the talent police. ๐
๐ 228
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.